Jonathan Gerber, MD of Levine Cancer Institute, discusses advances in research and treatment trends for AML at the 58th ASH Annual Meeting in San Diego, CA.
CD33, CD47, CAR T-cell and Novel Stem Cell Treatment Trends for 2017
Advertisement